Today 2026.06.10 D-93
Today 
|
Joint Symposium 3 (East Asia Collaborative Session) The CAR-T Landscape in East Asia: Approvals, Coverage, Domestic Development, and Regulatory Frameworks for Cell and Gene Therapy Sep. 18 (Fri), 10:10-11:50 |
Room A (1F) |
|
|---|---|---|
Insights into the Development of Cellular Therapy in China: Current Landscape and Future Directions
National Clinical Research Center for Hematologic Disease, China
TBD
University of Ulsan College of Medicine, Korea
TBD
TBD, TBD
TBD
TBD, TBD
|
Scientific Session 5 AML/MDS Biology Sep. 18 (Fri), 10:10-11:40 |
Room B (1F) |
|
|---|---|---|
| Chair(s) |
Jae-Sook Ahn (Chonnam National University Medical School, Korea) Chul Won Jung (Sungkyunkwan University School of Medicine, Korea) |
|
Stem Cell Regulation in AML
New York University Grossman School of Medicine, USA
Genomics for Precision Prediction of Treatment Response and Resistance in AML
Moffitt Cancer Center & Research Institute, USA
Information-driven Studeis on AML
College of Pharmacy, Seoul National University, Korea
|
Scientific Session 6 Potential Role of AI in Hematology and Cellular Therapy Sep. 18 (Fri), 10:10-11:40 |
Room C (2F) |
|
|---|---|---|
| Chair(s) |
Yoo Jin Kim (College of Medicine, The Catholic University of Korea, Korea) Jae-Yong Kwak (Jeonbuk National University Medical School, Korea) |
|
AI-Driven Prediction of Transplant Outcomes
University Hospital Essen, Germany
AI-Based Prediction of Early Relapse after CAR-T Therapy
University of California, San Francisco, USA
Clinical Relevance of BM fibrosis in MDS Using Digital Imaging Approaches
Seoul National University College of Medicine, Korea
|
Education Session 2 Toxicities of Transplant and Immunotherapy Sep. 18 (Fri), 10:10-11:40 |
Room D (2F) |
|
|---|---|---|
| Chair(s) |
Hyoung Jin Kang (Seoul National University College of Medicine, Korea) Hyeon Jin Park (National Cancer Center, Korea) |
|
Autoimmune Cytopenia and Pure Red Cell Aplasia after HSCT
Seoul National University College of Medicine, Korea
Best Anti-fungal Prophylaxis and Treatment pre-/post-HSCT
The Catholic University of Korea, Korea
Real World Management of CAR T Cell Toxicities-expert Opinion
Children's Hospital of Philadelphia, USA
|
Joint Symposium 4 (ISCT-KSBMT) Non-CAR T Cell Immunotherapy Sep. 18 (Fri), 13:00-14:30 |
Room A (1F) |
|
|---|---|---|
TBD
TBD, TBD
TBD
TBD, TBD
TBD
TBD, TBD
|
Scientific Session 7 Expanding CAR T-Cell Therapy beyond Lymphoid Malignancies: Myeloid Neoplasms, Solid Tumors, and Autoimmune Diseases Sep. 18 (Fri), 13:00-14:30 |
Room B (1F) |
|
|---|---|---|
| Chair(s) |
June-Won Cheong (Yonsei University College of Medicine, Korea) Sung-Hyun Kim (Dong-A University College of Medicine, Korea) |
|
Overcoming Barriers in CAR T - Cell Therapy for AML through Cytokine-armored CAR Design
Memorial Sloan Kettering Cancer Center, USA
Next-generation Switchable CAR-T Platform: Enhancing Precision and Efficacy in Solid Tumors
Seoul National University College of Medicine, Korea
Deep B Cell Depletion beyond Hematology: Immune Reset as a New Treatment Paradigm for Autoimmune Diseases
Erlangen-Nürnberg, Germany
|
Education Session 3 Practical Issues in Stem Cell Transplantation 2026 Sep. 18 (Fri), 13:00-14:30 |
Room D (2F) |
|
|---|---|---|
| Chair(s) |
Kyoung Ha Kim (Soonchunhyang University College of Medicine, Korea) Yong Park (Korea University College of Medicine, Korea) |
|
Recent Trends in Conditioning Regimens for Myeloid Malignancies
Chungnam National University College of Medicine, Korea
PTCy as a Universal Platform for GVHD Prophylaxis: Integrating New Standards and Defining the Remaining Role of ATG
Gregorio Marañón University General Hospital, Spain
Adult Cord Blood Transplantation Program for New Centers: A Practical Institutional Guide
Seoul National University College of Medicine, Korea
|
Presidential Symposium Lymphoma Cell Therapy Sep. 18 (Fri), 14:40-15:20 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Hyeon-Seok Eom (National Cancer Center, Korea) | |
Evolution of Cellular Therapies in Management of Lymphoma Patients
University of Pennsylvania, USA
|
Plenary Session 3 HSCT for Non-Malignant Disease Sep. 18 (Fri), 15:20-16:00 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Ho Joon Im (University of Ulsan College of Medicine, Korea) | |
Management of Mixed Chimerism and Graft Failure in Non-malignant Diseases
Dana-Farber Cancer Institute, USA
|
Debate Session 1 KOR Allogeneic HSCT in Patients with AML or MDS with TP53 Alternation Sep. 18 (Fri), 15:20-16:00 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Joon Ho Moon (Kyungpook National University School of Medicine, Korea) | |
To Transplant
Chonnam National University Medical School, Korea
Not to Transplant
Yonsei University College of Medicine, Korea
|
Debate Session 2 KOR HSCT for HLH: Decreased Conditioning Intensity vs. Increased Conditioning Intensity Sep. 18 (Fri), 17:30-18:20 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Kyung-Nam Koh (University of Ulsan College of Medicine, Korea) | |
Reduced Intensity Conditioning
University of Ulsan College of Medicine, Korea
Myeloablative Conditioning
Chonnam National University Medical School, Korea
|
Joint Symposium 5 (JSTCT-KSBMT) EBV-Associated Diseases and HSCT: From CAEBV to Post-Transplant Complications Sep. 18 (Fri), 16:50-18:30 |
Room C (2F) |
|
|---|---|---|
TBD
TBD, TBD
TBD
TBD, TBD
TBD
TBD, TBD
TBD
TBD, TBD
|
Scientific Session 8 Advances in HSCT Conditioning Sep. 18 (Fri), 16:50-18:20 |
Room D (2F) |
|
|---|---|---|
| Chair(s) |
Seong Kyu Park (Soonchunhyang University College of Medicine, Korea) Sang Kyun Sohn (Kyungpook National University School of Medicine, Korea) |
|
Optimal Conditioning in Allogeneic HSCT
Fred Hutchinson Cancer Center, USA
Allogeneic Hematopoietic Cell Donor Selection in 2026
Memorial Sloan Kettering Cancer Center, USA
Optimal Conditioning in Autologous HSCT
Seoul National University College of Medicine, Korea
